Cite
HARVARD Citation
Meric-Bernstam, F. et al. (2022). Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet oncology. 23 (12), pp. 1558-1570. [Online].